{"id":4292,"date":"2026-02-25T08:25:24","date_gmt":"2026-02-25T07:25:24","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?page_id=4292"},"modified":"2026-10-15T09:24:36","modified_gmt":"2026-10-15T07:24:36","slug":"pharma-location-suisse","status":"publish","type":"page","link":"https:\/\/www.interpharma.ch\/fr\/themen\/pharma-location-suisse\/","title":{"rendered":"Pharma Location Suisse"},"content":{"rendered":"\n \n
<\/div>\n \n
\n \n
\n

L\u2019industrie pharmaceutique est le principal moteur de l\u2019\u00e9conomie et de l\u2019innovation suisses. Elle investit quelque neuf milliards de francs par an dans la recherche et le d\u00e9veloppement, cr\u00e9e des emplois hautement qualifi\u00e9s et apporte chaque ann\u00e9e quelque dix milliards de francs d\u2019imp\u00f4ts. Elle g\u00e9n\u00e8re ainsi une valeur ajout\u00e9e qui va bien au-del\u00e0 de la branche proprement dite.<\/p>\n <\/div>\n <\/div>\n\n

<\/div>\n \n\n\n
<\/div>\n\n\n\n\n\n \n
<\/div>\n \n
\n \n
\n

La place pharmaceutique en chiffres<\/h2>\n <\/div>\n <\/div>\n\n
<\/div>\n \n\n\n\n
\n
\n
\n
\n

300\u2019800
\nEmplois
\n(2022)<\/p>\n<\/div>\n \n

\n
\n
\n

Indirects:<\/p>\n \n

250\u2019200<\/p>\n <\/div>\n \n

\n

Directs:<\/p>\n \n

50\u2019600<\/p>\n <\/div>\n <\/div>\n\n

\n
<\/div>\n \n
<\/div>\n <\/div>\n <\/div>\n\n

Multiplicateur: 5.9<\/p>\n <\/div>\n

\n

9.8% du PIB
\nValeur ajout\u00e9e brute
\n(74.5 mrd CHF, 2022)<\/p>\n<\/div>\n \n

\n
\n
\n

Indirecte:<\/p>\n \n

4.0%<\/p>\n <\/div>\n \n

\n

Directe:<\/p>\n \n

5.8%<\/p>\n <\/div>\n <\/div>\n\n

\n
<\/div>\n \n
<\/div>\n <\/div>\n <\/div>\n\n

Multiplicateur: 1.7<\/p>\n <\/div>\n

\n

40.5%
\nPart des exportations totales
\n(2024)<\/p>\n<\/div>\n \n

\n
\n
\n

Exportations:<\/p>\n \n

114.5 mrd CHF<\/p>\n <\/div>\n \n

\n

Importations:<\/p>\n \n

61.3 mrd CHF<\/p>\n <\/div>\n <\/div>\n\n

\n
<\/div>\n \n
<\/div>\n <\/div>\n <\/div>\n\n

Exc\u00e9dent: 53.2 mrd CHF<\/p>\n <\/div>\n <\/div>\n\n

\n

Source: BAK Economics (2024), Importance de l\u2019industrie pharmaceutique pour la Suisse; Office f\u00e9d\u00e9ral de la statistique (2024); Office f\u00e9d\u00e9ral de la douane et de la s\u00e9curit\u00e9 des fronti\u00e8res (2025)<\/p>\n <\/div>\n <\/div>\n <\/section>\n \n\n\n

<\/div>\n\n\n\n\n\n
\n
<\/div>\n\n
\n
\n

Contribution de la branche pharmaceutique par ann\u00e9e<\/h2>\n <\/div>\n \n
\n
\n
\n
\n \"\"\n <\/div>\n \n

Recherche et d\u00e9veloppement<\/p>\n \n

9 milliards<\/strong><\/p>\n

de francs suisses par ann\u00e9e<\/p>\n<\/h3>\n <\/div>\n <\/div>\n

\n
\n
\n \"\"\n <\/div>\n \n

Imp\u00f4ts g\u00e9n\u00e9r\u00e9s<\/p>\n \n

10 milliards \u2028<\/strong><\/p>\n

de francs suisses par ann\u00e9e<\/p>\n<\/h3>\n <\/div>\n <\/div>\n <\/div>\n\n

\n

Source: Interpharma (2025), Wellershoff & Partners (2025)<\/p>\n <\/div>\n <\/div>\n <\/section>\n \n\n\n

<\/div>\n\n\n\n\n\n
\n
<\/div>\n\n
\n
\n

La valeur ajout\u00e9e a un impact au-del\u00e0 de la branche<\/h2>\n <\/div>\n \n
\n
\n
\n

Patientes et patients<\/h3>\n \n

Acc\u00e8s aux m\u00e9dicaments innovants<\/p>\n <\/div>\n <\/div>\n

\n
\n

Fournisseurs<\/h3>\n \n

Commandes et valeur ajout\u00e9e r\u00e9gionale<\/p>\n <\/div>\n <\/div>\n

\n
\n

Hautes \u00e9coles<\/h3>\n \n

Coop\u00e9rations de recherche et transfert de connaissances<\/p>\n <\/div>\n <\/div>\n

\n
\n

Finances publiques<\/h3>\n \n

Imp\u00f4ts et taxes<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n \n\n\n

<\/div>\n\n\n\n\n\n
\n
\n

La politique des \u00c9tats-Unis affecte la place suisse<\/h2>\n <\/div>\n \n
\n
\n
\n

Syst\u00e8me de prix de r\u00e9f\u00e9rence<\/h3>\n \n
\n

Par leur syst\u00e8me de prix de r\u00e9f\u00e9rence, les \u00c9tats-Unis veulent relier leurs prix des m\u00e9dicaments aux prix europ\u00e9ens.<\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n

Pouvoir d\u2019achat et prix<\/h3>\n \n
\n

La Suisse a un fort pouvoir d\u2019achat et des prix relativement bas pour les m\u00e9dicaments.<\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n

Menaces de droits de douane<\/h3>\n \n
\n

Les menaces de droits de douane obligent les entreprises pharmaceutiques \u00e0 transf\u00e9rer de plus en plus de production et de recherche vers les \u00c9tats-Unis.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n

\n
\n

\n En r\u00e9sum\u00e9:<\/span> la politique d\u2019implantation et la r\u00e8glementation des prix sont en interaction croissante. <\/h2>\n <\/div>\n \n
\n

\u00c9tats-Unis, UE et Suisse en comparaison<\/h3>\n \n
\n
\n
\n

Chiffre d\u2019affaires des entreprises pharmaceutiques<\/p>\n

Valeur ajout\u00e9e<\/p>\n

D\u00e9penses pour les m\u00e9dicaments innovants<\/p>\n

Pouvoir d\u2019achat<\/p>\n <\/div>\n <\/div>\n\n

\n
\n

Chiffre d\u2019affaires des entreprises pharmaceutiques, part en pour cent<\/h4>\n <\/div>\n \n
\n

\u00c9tats-Unis<\/p>\n\n

\n

50%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

UE<\/p>\n\n

\n

22%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

Suisse<\/p>\n\n

\n

0.6%<\/p><\/div>\n <\/div>\n <\/div>\n \n

\n

Source: IQVIA (2025)<\/p>\n <\/div>\n <\/div>\n

\n
\n

Valeur ajout\u00e9e, part en pour cent<\/h4>\n <\/div>\n \n
\n

\u00c9tats-Unis<\/p>\n\n

\n

30%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

UE<\/p>\n\n

\n

33%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

Suisse<\/p>\n\n

\n

6.7%<\/p><\/div>\n <\/div>\n <\/div>\n \n

\n

Source: BAK Economics, 2026<\/p>\n <\/div>\n <\/div>\n

\n
\n

Ausgaben f\u00fcr innovative Medikamente gemessen am BIP, in Prozent<\/h4>\n <\/div>\n \n
\n

\u00c9tats-Unis<\/p>\n\n

\n

1.32%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

UE<\/p>\n\n

\n

0.62%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

Suisse<\/p>\n\n

\n

0.47%<\/p><\/div>\n <\/div>\n <\/div>\n \n

\n

Source: PhRMA, 2026<\/p>\n <\/div>\n <\/div>\n

\n
\n

Pouvoir d\u2019achat (PIB par habitant), en USD<\/h4>\n <\/div>\n \n
\n

\u00c9tats-Unis<\/p>\n\n

\n

USD 84'534<\/p><\/div>\n <\/div>\n <\/div>\n

\n

UE<\/p>\n\n

\n

USD 59'026<\/p><\/div>\n <\/div>\n <\/div>\n

\n

Suisse<\/p>\n\n

\n

USD 103'998<\/p><\/div>\n <\/div>\n <\/div>\n \n

\n

Source: Worldbank (2026)<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n \n\n\n

<\/div>\n\n\n\n\n\n
\n
<\/div>\n\n
\n
\n

La place suisse est sous pression<\/h2>\n\n
\n

L\u2019industrie a consid\u00e9rablement contribu\u00e9 \u00e0 faire de la Suisse une place d\u2019innovation actuellement en pointe \u00e0 l\u2019\u00e9chelon mondial. Mais les tensions g\u00e9opolitiques et les conflits commerciaux mettent la place pharmaceutique suisse sous pression.<\/p>\n <\/div>\n <\/div>\n \n

\n
\n

La part de la Suisse dans les investissements pharmaceutiques europ\u00e9ens est divis\u00e9e par deux<\/h3>\n \n
\n

Part de la Suisse dans le volume d\u2019investissements europ\u00e9ens 2016\u20132021<\/p>\n\n

\n

29%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

Part de la Suisse dans le volume d\u2019investissements europ\u00e9ens \u00e0 partir de 2022<\/p>\n\n

\n

12%<\/p><\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n

Croissance des investissements depuis 2021<\/h3>\n \n
\n

Europe<\/p>\n\n

\n

+212%<\/p><\/div>\n <\/div>\n <\/div>\n

\n

Suisse<\/p>\n\n

\n

+2.2%<\/p><\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n

\n

Source: BAK Economics (2026)<\/p>\n <\/div>\n <\/div>\n <\/section>\n\n\n\n

<\/div>\n\n\n\n\n\n
\n
<\/div>\n\n
\n
\n

Analyse de sc\u00e9nario: impact de la politique am\u00e9ricaine sur la croissance suisse<\/h2>\n <\/div>\n \n
\n
\n